BIOMARIN PHARMACEUTICAL INC
For the period ended Dec 31, 2023. Filed Feb 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 26, 2024
BMRN$57.13-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
| Page | |
|---|---|
| Exhibit Index | 76 |
| Financial Statements | |
| Reports of Independent Registered Public Accounting Firm (KPMG LLP, San Francisco, CA, Auditor Firm ID: 185) | 83 |
| Consolidated Financial Statements as of December 31, 2023 and 2022, and for the three years ended December 31, 2023: | |
| Consolidated Balance Sheets | 85 |
| Consolidated Statements of Operations | 86 |
| Consolidated Statements of Comprehensive Income (Loss) | 87 |
| Consolidated Statements of Changes in Stockholders’ Equity | 88 |
| Consolidated Statements of Cash Flows | 89 |
| Notes to Consolidated Financial Statements | 90 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.